A Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension

Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension

NCT01031680 ·Status: COMPLETED ·Phase: PHASE3

Study With Dapagliflozin

NCT02971618 ·Status: COMPLETED

Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes

NCT02796170 ·Status: COMPLETED ·Phase: PHASE4

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication

NCT01195662 ·Status: COMPLETED ·Phase: PHASE3

Comparison of the Effects of Dapagliflozin and Gemigliptin on Ketone Metabolism and Cardiac Remodeling in Type 2 Diabetes

NCT05194592 ·Status: UNKNOWN ·Phase: PHASE4

Study to Asses the Effect of Dapagliflozin on Central Blood Pressure Reduction.

NCT02919059 ·Status: UNKNOWN ·Phase: PHASE4

Dapagliflozin Post Marketing Surveillance in HF and CKD

NCT05134701 ·Status: COMPLETED

SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes

NCT05345327 ·Status: RECRUITING ·Phase: PHASE3

DAPAgliflozin Sodium Water glucosE EffecTs in Patients at High Cardiovascular Risk

NCT04258371 ·Status: UNKNOWN ·Phase: PHASE2

Effects Dapagliflozin on Inflammatory Markers Erythropoiesis and Iron Metabolism in Patients with Type 2 Diabetes and CKD

NCT06820567 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

Effects of SGLT2 Inhibitor on Hemodynamic Parameters in Resistant Hypertensive Subjects

NCT03089333 ·Status: COMPLETED ·Phase: PHASE4

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker

NCT01137474 ·Status: COMPLETED ·Phase: PHASE3

Dapagliflozin, Cardio-Metabolic Risk Factors and Type-2 Diabetes

NCT03377335 ·Status: UNKNOWN ·Phase: PHASE4

Effect of Dapagliflozin on Blood Pressure Variability in Prediabetes and Prehypertension

NCT03006471 ·Status: COMPLETED ·Phase: PHASE4

Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes

NCT05139914 ·Status: TERMINATED ·Phase: PHASE4

Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes

NCT02914691 ·Status: COMPLETED ·Phase: PHASE4

Head-to-head Comparison of Empagliflozin and Dapagliflozin

NCT03748810 ·Status: COMPLETED

A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients

NCT02616666 ·Status: COMPLETED ·Phase: PHASE4

Effect of Dapagliflozine on Systemic and Renal Endothelial Function

NCT02501616 ·Status: UNKNOWN ·Phase: PHASE4

Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)

NCT02973477 ·Status: COMPLETED ·Phase: PHASE4

Dapagliflozin Treatment in Type 2 Diabetes

NCT04620590 ·Status: COMPLETED ·Phase: PHASE4

A Clinical Study to Investigate the Effects of Dapagliflozin on Heart Work, Heart Nutrient Uptake, and Heart Muscle Efficiency in Type 2 Diabetes Patients

NCT03387683 ·Status: COMPLETED ·Phase: PHASE4

Effect of Dapagliflozin on Renal Outcomes and Bone Mineral Disease in Non-diabetic Chronic Kidney Disease Patients

NCT05735197 ·Status: COMPLETED ·Phase: PHASE4

A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD

NCT02547935 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Effects Of Sodium Glucose Cotranspoter 2 Inhibitors On Heart And Kidneys In Fabry Disease Patients

NCT05710367 ·Status: UNKNOWN ·Phase: PHASE2